4
Changes in Ownership
Atea Pharmaceuticals, Inc. Filed Acc 0000950170-25-013852
Chief Commercial Officer gave up 11,517 shares (to pay taxes)
- Chief Commercial Officer acquired 8,750 shares (grant or award)
- Chief Commercial Officer acquired 33,333 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Vavricka John Chief Commercial Officer | 2025-01-31 | Option exercise | +33,333 | 54,848 | D | ||
| Vavricka John Chief Commercial Officer | 2025-01-31 | Grant or award | +8,750 | 63,598 | D | ||
| Vavricka John Chief Commercial Officer | 2025-01-31 | Shares withheld for taxes | −11,517 | $3.06 | $35,242 | 52,081 | D |
| Derivatives | |||||||
| Vavricka John Chief Commercial Officer | 2025-01-31 | Option exercise · Restricted Stock Units | −33,333 | 33,333 | D | ||
| Vavricka John Chief Commercial Officer | 2025-01-31 | Grant or award · Restricted Stock Units | +8,750 | 8,750 | D | ||
| Vavricka John Chief Commercial Officer | 2025-01-31 | Grant or award · Stock Option (Right to Buy) | +132,800 | 132,800 | D | ||
Loading xslF345X05/ownership.xml…